The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2020 | The role of CAR T-cell therapy in DLBCL
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses the impact of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). CAR T-cell therapy represents an important and promising tool for patients that have failed previous treatment strategies. Dr Sureda reveals that a significant proportion of patients still relapse after CAR T-cell therapy and outlines the strategies to overcome this challenge. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.
